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Acrodermatitis enteropathica is an autosomal recessive
disease characterized by skin involvement due to defec-
tive intestinal zinc absorption. Usually, the skin lesions
include erythema, erosions, and small blisters in perior-
al, perianal regions, and hands and feet, which develop
soon after weaning from the breast. The acrodermatitis
enteropathica gene has been localized to chromosomal
region 8q24.3 and subsequently the SLC39A4 gene has
been disclosed as the acrodermatitis enteropathica gene.
SLC39A4 mutations have been demonstrated in several
acrodermatitis enteropathica families, and in this study
we have examined two Japanese acrodermatitis entero-
pathica families for SLC39A4 mutations. The mutation
detection strategy consisted of polymerase chain reac-
tion ampli¢cation of all 12 exons and £anking intronic
sequences, followed by direct nucleotide sequencing. It
revealed three novel mutations, 1017ins53, which creates
a premature termination codon, and two mis-sense mu-
tations, R95C and Q303H. Key words: autosomal recessive
disease/zinc de¢ciency/zinc and iron-regulated transporter-like
protein. J Invest Dermatol 120:963 ^966, 2003
A
crodermatitis enteropathica (AE; OMIM 201100) is
a rare autosomal recessive disease that manifests
with acral dermatitis and low serum zinc levels. It
was ¢rst named by Danbolt and Closs in 1943, and
the pathogenesis of the disease had been unknown
until Barnes and Moynahan (1973) observed that the disorder
was caused by the inability to absorb su⁄cient zinc.The di¡eren-
tial diagnosis of AE includes acquired zinc de¢ciency syndrome
due to a low zinc level in mother’s milk because both conditions
are quite similar in terms of onset and clinical presentation.
As soon as the low zinc breast-feed infants were weaned, they
no longer require supplemental zinc, whereas AE patients experi-
ence recurrence of symptoms after discontinuation of oral zinc
therapy.
Huang and Gitschier (1997) demonstrated that the lethal milk
mouse, which was thought to be an animal counterpart of AE, is
associated with a ZNT4 gene mutation, strongly suggesting a re-
lationship between AE and the human ZNT4 gene; however, no
pathogenetic ZNT4 mutations were identi¢ed in AE patients in
several studies (Bleck et al, 2001; Kˇry et al, 2001; Nakano et al,
2002).
Recently, linkage analysis revealed that the AE gene locus re-
sides on chromosome 8q24.3 (Wang et al, 2001) and the SLC39A4
gene (SLC, solute carrier) family 39, member 4, has been dis-
closed as a causative gene for AE (Kˇry et al, 2002; Wang et al,
2002). The SLC39A4 gene encodes one member of a human
zinc/iron-regulated transporter-like protein (hZIP) family, hZIP4
(Wang et al, 2002). This gene consists of a total of 12 exons and
the corresponding 2.5 kb mRNA encodes a polypeptide of 647
amino acids, having eight transmembrane domains organized in
two blocks of three and ¢ve. A histidine-rich region, which is a
putative zinc-binding site, resides between the two blocks of
transmembrane domains (Guerinot, 2000; Kˇry et al, 2002;Wang
et al, 2002). Expression of hZIP4 mRNA was observed to be
abundant in the small intestine, stomach, and colon, as well as
in the kidney, and immunohistochemistry revealed that the pre-
sumed zinc-uptake protein was localized to the apical membrane
of the enterocyte in mouse colon (Kˇry et al, 2002; Wang et al,
2002). Little is known about the function of hZIP4, although
three other members of the ZIP family (hZIP1, hZIP2, and
hZIP3) have been shown to transport zinc into the cytoplasm
(Gaither and Eide, 2000a, 2000b).
In this study, we identi¢ed three novel mutations in the human
SLC39A4 gene in two Japanese AE families.
MATERIALS ANDMETHODS
Clinical details and diagnostic features Two Japanese families were
studied, which were summarized in Nakano et al (2002). The use of
human tissue was approved by the Ethics Committee of Hirosaki
University School of Medicine.
Family 1 Two 11 mo old female identical twins, now aged 8 y, were third
and fourth children of healthy Japanese parents, who are not known to be
related (Fig 1). Their older sister and brother had no history of acral derma-
titis. The patients had blisters and erythema on their ¢ngers and toes, and
perioral and perianal regions at the age of 10 mo (Fig 2A^C). At the time
of their ¢rst examination, the serum zinc levels of P=1 and P=2 in Fig 1
were below the normal range of 59^135 mg per dl (20 mg per dl and 36 mg
per dl, respectively). Hair zinc levels of the elder patient (P-1) was 68 mg per
g, also below the normal range of 148 7 41.5 mg per g. The serum zinc
levels of their parents and siblings were normal. Histopathologic examina-
tion from the right dorsal foot of P-1 revealed pale staining of the corneal
layer and an epidermal acantholytic blister (Fig 2D). After oral zinc sulfate
treatment, blisters and erythema disappeared and their serum zinc level
was within the normal range. At the age of 2.5 y, their mother disconti-
nued zinc treatment, and they had a recurrence of skin involvement and
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remarkably low level of serum zinc. This clinical course suggested that
their clinical diagnosis was congenital AE.
Family 2 A 9 mo old male infant, now aged 11 y, was the ¢rst child of
healthy Japanese parents who are third cousins (Fig 1). There were no other
a¡ected individuals in this family, including his younger sister. He had acral
erythematous plaques and small blisters at the age of 7 mo. His serum zinc
level was undetectable, under 10 mg per dl, and his serum alkaline phospha-
tase level was 89 IU per liter, signi¢cantly below the normal range of 633
7 192 IU per liter. The serum zinc and serum alkaline phosphatase levels
of his parents and sister were normal. Oral zinc sulfate treatment was e¡ec-
tive, however, discontinuation of the treatment resulted in recurrence of
dermatitis and a low serum zinc level, which suggested AE. The details of
these cases have been reported previously (Mikami et al, 1994).
Mutational analysis of human SLC39A4 gene Informed consent was
obtained from all participating family members and controls. DNA was
extracted from peripheral blood samples from the probands, their parents,
and close relatives using QIAamp Blood Maxi Kit (Qiagen,Valencia, CA).
Control blood samples from 50 unrelated healthy individuals with no
evidence of a skin disease were also obtained and DNA extracted.
Human SLC39A4 cDNA and genomic DNA sequence (GenBank
accession number NM 130849 and AF205589, respectively) were used to
design primer pairs (Table I) and polymerase chain reaction (PCR)
ampli¢cation of the entire coding region was performed. PCR products
were analyzed by direct nucleotide sequencing (ABI PRISM 310, Perkin-
Elmer Cetus, Foster City, CA). The mutations were veri¢ed by restriction
endonuclease digestion of PCR products from family members. As the
probands and their father in family 1 showed two distinct PCR products
of exon 6, each of them was subcloned using pGEM-T and pGEM-T easy
vector systems to isolate the coding PCR product (Promega, Madison,
WI). Positive colonies were subjected directly to PCR ampli¢cation using
the same primers, and the resulting PCR products were analyzed by direct
nucleotide sequencing.
RESULTS AND DISCUSSION
In this study, we identi¢ed a novel premature termination codon
mutation and two mis-sense mutations in two Japanese AE fa-
milies. The positions of these mutations are depicted in Fig 3 to-
gether with SLC39A4 mutations disclosed thus far in AE
patients. During this screening, there was no evidence of coam-
pli¢cation of pseudogenes.
In family 1, screening of SLC39A4 for pathogenetic mutations
revealed that the two identical twins were heterozygous for a 53
bp insertion at nucleotide position 1017 and a C toT substitution
at the nucleotide position 283. Agarose gel electrophoresis of the
resulting PCR products demonstrated an additional longer band
in the probands and their father, but not in the mother and the
control, suggesting that the mutation was a small insertion in
exon 6 of paternal origin (Fig 4A). Subcloning procedure con-
¢rmed that there was a 53 bp insertion at nucleotide position
1017, designated 1017ins53 (Fig 4B). This mutation causes a frame-
shift and a premature termination codon immediately down-
stream from the insertion site. The production of a truncated
protein missing the last seven of eight transmembrane domains
as well as the zinc-binding site (Fig 3). Further screening revealed
a nucleotide substitution 283C-T in exon 2, resulting in a
change from arginine (CGC) to cysteine (TGC) at amino acid
position 95, R95C (Fig 4C). This mutation abolishes a restriction
enzyme site for FauI. Restriction digestion revealed that the
R95C was of maternal origin (data not shown). Screening of
100 chromosomes in healthy, una¡ected control subjects by FauI
digestion was negative demonstrating that R95C is probably not
a simple polymorphism but a disease-causing pathogenetic muta-
tion. The implication of the R95C substitution is di⁄cult to as-
sess, as the sequence in this region is unique to hZIP4 (Wang et al,
Figure1. Pedigrees of family 1 and family 2 with AE. The solid
symbols ( ) indicate maternal mutations and the dotted symbols ( ) indi-
cate paternal mutations in family 1. The diagonal stripe symbols ( ) refer
to mutations in family 2. The open symbols refer to clinically una¡ected
individuals. The parents of family 2 are related.
Figure 2. Clinical and histopathologic ¢ndings of patient 1 (P-1) in
family 1 at the initial examination. Erythema, erosions, blisters, and
crusts are shown in perioral and perianal regions and acral sites of the feet
(A^C). The biopsy specimen from right dorsal foot, square box in C,
showed pale staining of corneal layer, spongiosis, and epidermal acantholy-
tic blister (D). Scale bar: 50 mm; Hematoxylin and eosin stain, original
magni¢cation100.
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2002) and functional data is lacking for hZIP4 as well as many of
the other members of this gene family.
Screening of the SLC39A4 gene in family 2 revealed that the
parents were heterozygous for a G to C substitution at nucleotide
position 909 in exon 5, whereas the a¡ected individual was
homozygous for this mutation (Fig 4D). The healthy sister was
not a carrier. This nucleotide substitution resulted in a change
from a glutamine (CAG) to histidine (CAC) at amino acid posi-
tion 303, designated Q303H. This mutation creates a new restric-
tion enzyme site for BstXI. Restriction digestion of the exon 5
PCR product with the enzyme of 100 chromosomes in healthy,
unrelated controls was negative for Q303H mutation.This single-
nucleotide mutation 909G-C leads to a substitution of highly
conserved amino acid in the proteins of the ZIP family (seeWang
et al, 2002). In fact, as the ZIP4 sequence has been identi¢ed only
in humans and Arabidopsis thaliana (Guerinot, 2000), and other
mammalian ZIP4 proteins have not yet been identi¢ed, we could
not compare amino acid conservation between mammalian ZIP4
genes. The patient a¡ected with AE in this study, however, was
homozygous for this novel mis-sense mutation, whereas hetero-
zygous carriers had no evidence of AE. Furthermore, this muta-
tion was not present in any of the 50 una¡ected and unrelated
individuals we studied. Thus, it is not merely common poly-
morphism but more likely a pathogenetic mutation.
In a previous study, (Wang et al, 2002; Kuº ry et al, 2002) three
mis-sense mutations and a splicing mutation were not proven to
be mutations (Fig 3). The P84L, which was identi¢ed in two af-
fected individuals in the homozygous state and in one in the
compound heterozygous state, was also detected in three of 120
control chromosomes (Wang et al, 2002). The R251W, probably
resulting from 751C-T, is possibly a polymorphism because the
cDNA sequence (NM 130849) shows a C at the nucleotide posi-
tion 751, whereas the genomic DNA sequence (AF205589) shows
aT.Whether 192 þ 19G-A, originally reported as 193 ^ 19G-
A by Kˇry et al (2002) is a pathogenetic mutation is also unclear.
Because the þ19 position is far from the exon^intron border,
and evidence for altered transcripts resulting from mis-splicing
is lacking, de¢nite conclusions cannot be drawn.
The fact that simple administration of oral zinc can overcome
zinc de¢ciency in AE patients is still enigmatic. One explanation
is that there may be another zinc transporter in the intestine,
which is less e⁄cient in its ability to transport zinc compared
with hZIP4, but can compensate for the defect in SLC39A4
when excess zinc is supplied in the diet.
In conclusion, all three of the a¡ected patients we investigated
carry pathogenetic mutations on both SLC39A4 alleles, support-
ing the hypothesis that SLC39A4 is a candidate gene for AE.
Table I. Primers for ampli¢cation of the SLC39A4 gene
Exon 50 primer 30 primer Product size (bp) AT (1C)
1 TGGACAACCCCAGCAAAGCC GTGCCCAGGTACTGCCACTA 410 62
^90 in cDNAa þ 128
2 CATCAAATTGGCAGTGGCTC CCGAAGGCTTTGCAGCCAGG 623 58
^256 þ 85
3 TGGATGGCAGAAGGTCACAC CTGGCAGGGAGAAGAGTTGG 362 62
^53 þ 116
4 GATTCCCCAGCCTCCACGTC ATCACGTCCCTGGCACTCAG 319 62
^79 þ 103
5 CTCATCAGCTCCAGCAACAG ACTCTCTCCATCCCTCATCC 382 60
^116 þ 94
6 CAGGAGAGTGGGGCTTTGAG GAGGTGGGGTGGGTAAAGTC 411 58
^146 þ 92
7 ACCTCCTGACCCCTCTCCCT TACCTTCCCAAGAAGCCTGA 238 60
^79 þ 21
8 CTCTTCAATCTCCTGCTGCC TGGGAGTGTGGGCGTGGGAA 313 60
^109 þ 72
9 ACCGCGTTCCTCCTCCACTT TTCGCGTGGCCTGTCGCCTA 206 60
^51 þ 100
10 TAGGCGACAGGCCACGCGAA TGTTCCAGGTCTCCCCGCCCA 265 62
^43 þ 69
11 TAAGAGGGCGGGACCGAAAG AGCTGAGGAGCAAGTGGGCA 360 57
^68 þ 94
12 ACATGGTCAGGATGGCGAGG TGGTTTCTGGGCTGTAGGTT 294 57
^97 2012 in cDNA
AT, annealing temperature.
aGenerated from the corresponding exon^intron border.
Figure 3. Schematic illustration of the SLC39A4 polypeptide and
positions of all SLC39A4 mutations disclosed thus far in AE pa-
tients. The mis-sense mutations are shown above the molecule, whereas
the premature termination codon and the putative splice site mutation are
shown below. The mutations disclosed in this study are shown in bold
type. Four mutations with asterisk are not con¢rmed as a mutation.
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Figure 4. Identi¢cation of the SLC39A4 mutations. Two percent agarose gel electrophoresis of the PCR products spanning exon 6 showed double
bands in the a¡ected individuals and father in family 1 (P-1, P-2, and F) (A). Direct nucleotide sequencing of the PCR products spanning exon 6 revealed
a heterozygous 1017ins53 in these individuals (B, middle panel). The 1017ins53 mutation, which is the duplication of 53 bp from the nucleotide position 1017,
was veri¢ed by sequencing of the subcloned mutant band (B, top panel). Sequencing of the PCR products spanning exon 2 revealed a heterozygous 283
C-T, designated R95C, in the a¡ected individuals and mother (P-1, P-2, and M) (C, upper panel). In family 2, the patient was homozygous for 909
G-C, designated Q303H (D, upper panel), whereas the parents were heterozygous for this mutation (D, middle panel). MW, molecular weight markers 100
bp DNA Ladder; M, mother; F, father; C, control.
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